IMAC Holdings, Inc. is a clinical research and commercialization company. Co. is focused on innovative medical advancements and care in the oncology, neurological, and orthopedic medical specialties. Co. is focused on providing natural, non-opioid solutions to pain as consumers demand conservative treatments for an aging population. Its Investigational New Drug division conducted a clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson's disease. Co. is also engaged in providing the precision medicine business. The BACK average annual return since 2019 is shown above.
The Average Annual Return on the BACK average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BACK average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BACK average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|